Provided by Tiger Fintech (Singapore) Pte. Ltd.

Acumen Pharmaceuticals, Inc.

0.9008
-0.0792-8.08%
Post-market: 0.90080.00000.00%19:59 EDT
Volume:487.31K
Turnover:446.65K
Market Cap:54.56M
PE:-0.53
High:1.02
Open:0.9800
Low:0.8686
Close:0.9800
Loading ...

Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

THOMSON REUTERS
·
01 Apr

Acumen Pharmaceuticals’ Promising Alzheimer’s Strategy Earns Buy Rating with Revised Price Target

TIPRANKS
·
29 Mar

Acumen Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
28 Mar

UBS Cuts Price Target on Acumen Pharmaceuticals to $4 From $6, Keeps Buy Rating

MT Newswires Live
·
28 Mar

Acumen Pharmaceuticals Inc (ABOS) Q4 2024 Earnings Call Highlights: Strong Financial Position ...

GuruFocus.com
·
28 Mar

Q4 2024 Acumen Pharmaceuticals Inc Earnings Call

Thomson Reuters StreetEvents
·
28 Mar

Acumen Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
27 Mar

Acumen Pharmaceuticals FY 2024 EPS $(1.71) Misses $(1.55) Estimate

Benzinga
·
27 Mar

BRIEF-Acumen Pharmaceuticals, Inc. FY Income From Operations USD -114.017 Million

Reuters
·
27 Mar

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2024 and Business Highlights

THOMSON REUTERS
·
27 Mar

Acumen Pharmaceuticals, Inc. FY Net Income USD -102.329 Million

THOMSON REUTERS
·
27 Mar

Acumen Pharmaceuticals, Inc. FY Basic EPS USD -1.71

THOMSON REUTERS
·
27 Mar

Acumen Pharmaceuticals, Inc. FY Income From Operations USD -114.017 Million

THOMSON REUTERS
·
27 Mar

Acumen Pharmaceuticals, Inc. FY Operating Expenses USD 114.017 Million

THOMSON REUTERS
·
27 Mar

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2024 and Business Highlights

GlobeNewswire
·
27 Mar

BRIEF-Acumen Pharmaceuticals Completes Enrollment Of Altitude-Ad, A Phase 2 Clinical Trial Of Sabirnetug (Acu193) In Early Alzheimer’S Disease

Reuters
·
26 Mar

Acumen Pharmaceuticals Inc - Topline Results Expected in Late 2026

THOMSON REUTERS
·
26 Mar

Acumen Pharmaceuticals Completes Enrollment of Altitude-Ad, a Phase 2 Clinical Trial of Sabirnetug (Acu193) in Early Alzheimer’s Disease

THOMSON REUTERS
·
26 Mar

Acumen Pharmaceuticals Inc expected to post a loss of 48 cents a share - Earnings Preview

Reuters
·
25 Mar

Acumen Pharmaceuticals Inc expected to post a loss of 48 cents a share - Earnings Preview

Reuters
·
21 Mar